Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323618 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1308683 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1310240 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1309368 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3088557 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1309450 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1308718 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL2131918 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3088558 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL855342 | 0.96 | GSR (0.52) | GSRCPB2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118348134-A | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI and VII | 华盛顿大学商业中心 | 2024-07-16 | — | — | CN | disclosed |
| CN-112986429-B | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI and VII | 华盛顿大学商业中心 | 2024-03-29 | — | — | CN | disclosed |
| US-11618764-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-04-04 | — | — | US | disclosed |
| CN-110542728-B | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI and VII | 华盛顿大学商业中心 | 2022-05-24 | — | — | CN | disclosed |
| EP-3192529-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-3485912-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20190144916-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-05-16 | — | — | US | disclosed |
| US-10196668-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3192529-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2416804-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-0738144-A1 | PHENYLMETHYL HEXANAMIDES, AND THE USE THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| EP-0498801-A4 | SOLID SURFACE FOR PEPTIDE SYNTHESIS | — | 1993-03-31 | — | — | EP | disclosed |
| US-5162307-A | Treatment of emphysema | BOARD OF TRUSTEES OF THE UNIVERSITY OF KENTUCKY (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0498801-A1 | SOLID SURFACE FOR PEPTIDE SYNTHESIS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1992-08-19 | — | — | EP | disclosed |
| EP-0396709-A4 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | — | 1991-05-22 | — | — | EP | disclosed |
| WO-1991004266-A1 | SOLID SURFACE FOR PEPTIDE SYNTHESIS | COSELCO MIMOTOPES PTY LTD. (AU) | 1991-04-04 | — | — | WO | disclosed |
| EP-0396709-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-11-14 | — | — | EP | disclosed |
| EP-0368449-A2 | Elastase inhibiting polymers and methods to produce them | Digenis, George Alexander (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0367514-A2 | Human leukocyte elastase inhibitors and methods for producing and using same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-09 | — | — | EP | disclosed |
| WO-1990004409-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144916-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | GAA, MAN2B1, CLN6 | DPP4 553/4885GSR 2894/4885CPB2 128/4885 |
| US-10196668-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | GAA, GBA1, MAN2B1 | DPP4 631/4885GSR 3793/4885CPB2 150/4885 |
| US-11618764-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | GAA, MAN2B1, CLN6 | DPP4 553/4885GSR 2894/4885CPB2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.